WLS/GPR177 is specifically required for Wnt signaling, a key pathway in osteoblast differentiation and function and that has been the focus of our research for more than a decade. Specifically, deletion of WLS makes any cell incapable of secreting any Wnt protein. This competitive renewal will test whether the actions of WLS within cells of the osteoblast lineage affect bone mass. This builds on our work examining the importance of the Wnt receptors, Lrp5 and Lrp6, in establishing and maintaining normal bone mass within the osteoblast lineage. Two single nucleotide polymorphisms (SNPs) located within an intron of the GPR177/Wntless gene (WLS) on human chromosome 1p31.3 are associated with significant reductions in bone mineral density (BMD) in the lumbar spine and femoral neck. While these studies identify WLS as a candidate gene in establishing and maintaining BMD, the results need to be validated and a molecular mechanism determined to put the information into biological context. A key step is to identify the cell type(s) in which the gene product functions o impact BMD. We will do this by creating genetically engineered mouse models in which Wls deficiency is restricted to specific cell types.
Two specific aims will test the overarching hypothesis that WLS/GPR177 functions within osteoblasts to control bone formation and/or homeostasis.
Specific Aim 1 will focus on examining Wls function in differentiated osteoblasts.
Sub aims will include characterizing the phenotypes associated with Osteocalcin-cre- mediated conditional deletion of Wls in osteoblasts, assessing the function in Wls in osteoblasts of skeletally mature mice by using a tamoxifen-inducible cre (Col1a1-cre), and crossing mice with high bone mass due to an Lrp5 mutation to those lacking Wls to examine the resulting phenotype.
Aim 2 will examine the role of Wls within osteochondral progenitors by using Dermo1-cre mediate Wls deletion. In addition, differentiation of Wls- deficient and control primary calvarial osteoblasts will be compared to assess mechanisms which underlie the deficiencies in bone mass we have seen in our preliminary studies examining mice with targeted deletions of Wls in the osteoblast lineage.

Public Health Relevance

WLS/GPR177 is specifically required for Wnt signaling, a key pathway in osteoblast differentiation and function and that has been the focus of our research for more than a decade. Specifically, deletion of WLS makes any cell incapable of secreting any Wnt protein. This competitive renewal will test whether the actions of WLS within cells of the osteoblast lineage affect bone mass. This builds on our work examining the importance of the Wnt receptors, Lrp5 and Lrp6, in establishing and maintaining normal bone mass within the osteoblast lineage.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
2R01AR053293-06
Application #
8400822
Study Section
Special Emphasis Panel (ZRG1-MOSS-A (02))
Program Officer
Chen, Faye H
Project Start
2005-12-01
Project End
2017-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
6
Fiscal Year
2012
Total Cost
$427,500
Indirect Cost
$202,500
Name
Van Andel Research Institute
Department
Type
DUNS #
129273160
City
Grand Rapids
State
MI
Country
United States
Zip Code
49503
Michalski, Megan N; Williams, Bart O (2018) A quest for clarity in bone erosion: The role of sequestosome 1 in Paget's disease of bone. J Biol Chem 293:9542-9543
Madan, Babita; McDonald, Mitchell J; Foxa, Gabrielle E et al. (2018) Bone loss from Wnt inhibition mitigated by concurrent alendronate therapy. Bone Res 6:17
Yang, Tao; Williams, Bart O (2017) Low-Density Lipoprotein Receptor-Related Proteins in Skeletal Development and Disease. Physiol Rev 97:1211-1228
Williams, Bart O; Warman, Matthew L (2017) CRISPR/CAS9 Technologies. J Bone Miner Res 32:883-888
Weivoda, Megan M; Ruan, Ming; Hachfeld, Christine M et al. (2016) Wnt Signaling Inhibits Osteoclast Differentiation by Activating Canonical and Noncanonical cAMP/PKA Pathways. J Bone Miner Res 31:65-75
Williams, Bart O (2016) Genetically engineered mouse models to evaluate the role of Wnt secretion in bone development and homeostasis. Am J Med Genet C Semin Med Genet 172C:24-6
Schumacher, Cassie A; Joiner, Danese M; Less, Kennen D et al. (2016) Characterization of genetically engineered mouse models carrying Col2a1-cre-induced deletions of Lrp5 and/or Lrp6. Bone Res 4:15042
Burgers, Travis A; Vivanco, Juan F; Zahatnansky, Juraj et al. (2016) Mice with a heterozygous Lrp6 deletion have impaired fracture healing. Bone Res 4:16025
Zhong, Zhendong A; Peck, Anderson; Li, Shihong et al. (2015) (99m)TC-Methylene diphosphonate uptake at injury site correlates with osteoblast differentiation and mineralization during bone healing in mice. Bone Res 3:15013
Zhong, Zhendong A; Zahatnansky, Juraj; Snider, John et al. (2015) Wntless spatially regulates bone development through ?-catenin-dependent and independent mechanisms. Dev Dyn 244:1347-55

Showing the most recent 10 out of 39 publications